BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 22433303)

  • 1. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
    Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
    Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
    Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.
    Villa E; Grottola A; Buttafoco P; Colantoni A; Bagni A; Ferretti I; Cremonini C; Bertani H; Manenti F
    Am J Gastroenterol; 2001 Oct; 96(10):2973-7. PubMed ID: 11693335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reflections on the treatment of EDM in hepatitis C virus patients treated with interferon alpha from a retrospective survey concerning 29 patients].
    Lang JP; Halleguen O; Vecchionacci V; Doffoel M
    Encephale; 2003; 29(3 Pt 1):273-7. PubMed ID: 12876553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical features and natural history of post-transfusion hepatitis C].
    Chong YT; Lin CS; Zhao ZX; Lin GL; Li JG; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2006 Mar; 14(3):199-201. PubMed ID: 16556415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis.
    Rao H; Yang X; Tan Y; Ning Q; Yang D; Wang J; Yang Y; Zheng S; Yang D; Hou J; Xie Q; Zhao C; Zhang L; Mao X; Sun T; Bai L; Zhang F; Jin J; Zhao Y; Wang M; Xie W; Ma Y; Quan J; Yan X; An P; Lin F; Jia J; Hu X; Gong Z; Wu J; Chen Y; Jia Z; Lin M; Wang G; Zhu Y; Zhang Y; Xie H; Luo L; Ren Q; Huang R; Wei L
    J Clin Transl Hepatol; 2020 Sep; 8(3):255-261. PubMed ID: 33083247
    [No Abstract]   [Full Text] [Related]  

  • 13. [A five-year follow-up of one hundred and thirty-six patients of hepatitis C].
    She LH; Lin CS; Cai QX; Zhang XH; Wu YK; Zhao ZX; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):823-7. PubMed ID: 22433303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of hepatitis C: patients with cirrhosis.
    Schalm SW; Fattovich G; Brouwer JT
    Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.